Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: A novel autoinflammatory syndrome was recently described in male patients who harbored somatic mutations in the X-chromosomal UBA1 gene. These patients were characterized by adult-onset, treatment-refractory inflammation with fever, cytopenia, dysplastic bone marrow, vacuoles in myeloid and erythroid progenitor cells, cutaneous and pulmonary inflammation, chondritis, and vasculitis, which is abbreviated as VEXAS.
Objective: This study aimed to (retrospectively) diagnose VEXAS in patients who had previously been registered as having unclassified autoinflammation. We furthermore aimed to describe clinical experiences with this multifaceted, complex disease.
Methods: A systematic reanalysis of whole-exome sequencing data from a cohort of undiagnosed patients with autoinflammation from academic hospitals in The Netherlands was performed. When no sequencing data were available, targeted Sanger sequencing was applied in cases with high clinical suspicion of VEXAS.
Results: A total of 12 male patients who carried mutations in UBA1 were identified. These patients presented with adult-onset (mean age 67 years, range 47-79 years) autoinflammation with systemic symptoms, elevated inflammatory parameters, and multiorgan involvement, most typically involving the skin and bone marrow. Novel features of VEXAS included interstitial nephritis, cardiac involvement, stroke, and intestinal perforation related to treatment with tocilizumab. Although many types of treatment were initiated, most patients became treatment-refractory, with a high mortality rate of 50%.
Conclusion: VEXAS should be considered in the differential diagnosis of males with adult-onset autoinflammation characterized by systemic symptoms and multiorgan involvement. Early diagnosis can prevent unnecessary diagnostic procedures and provide better prognostic information and more suitable treatment options, including stem cell transplantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2021.05.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sterile osteomyelitis: a cardinal sign of autoinflammation.
Reumatologia
December 2024
Department of Internal Medicine, Trofa Saúde Hospital Privado em Gaia, Vila Nova de Gaia, Portugal.
Autoinflammatory bone disorders (ABDs) are characterized by sterile bone inflammation stemming from dysregulated innate immune responses. This review focuses on the occurrence of sterile osteomyelitis in ABDs and related diseases, notably chronic nonbacterial osteomyelitis (CNO) and its sporadic and monogenic forms, such as deficiency of the interleukin-1 (IL-1) receptor antagonist, Majeed syndrome, CNO related to mutation, and pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA syndrome). Additionally, other autoinflammatory disorders (AIDs) are discussed, including classical periodic fever syndromes (e.
View Article and Find Full Text PDFAcquired autoinflammatory disorders: a dermatologist's perspective.
Clin Exp Dermatol
April 2025
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Article Synopsis
- Autoinflammatory disorders are characterized by an exaggerated response of the innate immune system, primarily involving neutrophils and macrophages, and are differentiated from connective tissue diseases by the absence of anti-nuclear antibodies.
- Many of these disorders are linked to inherited genetic mutations and tend to manifest in childhood or early adulthood, though some, like VEXAS syndrome, highlight the potential for acquired mutations in adults.
- The review focuses on the cutaneous manifestations of various acquired autoinflammatory disorders, including adult-onset Still's disease and Schnitzler syndrome, which have significant diagnostic implications.
How underappreciated autoinflammatory (innate immunity) mechanisms dominate disparate autoimmune disorders.
Front Immunol
October 2024
Department of Internal Medicine, Division of Rheumatology, Marmara University School of Medicine, Istanbul, Türkiye.
Article Synopsis
- The text talks about how our immune system can mistakenly attack our own body, which is called autoimmunity. It explains how scientists have learned about different types of immune responses over time.
- It introduces new ideas like "auto inflammation" to show a different way our immune system can act up against itself, beside the old ideas of autoimmunity.
- The text also mentions specific diseases, like rheumatoid arthritis and psoriasis, and explains how both parts of the immune system (innate and adaptive) work together in these conditions.
Schnitzler Syndrome: Insights into Its Pathogenesis, Clinical Manifestations, and Current Management.
Biomolecules
May 2024
Dermatologic Clinic, University Hospital of Strasbourg, 67091 Strasbourg, France.
Article Synopsis
- * The disease shows similarities with other autoinflammatory disorders and highlights the significant role of interleukin-1 inhibitors in its treatment, pointing to this cytokine's importance in its development.
- * Despite some insights, the exact causes of Schnitzler syndrome and its connection between autoinflammatory symptoms and monoclonal gammopathy remain largely unknown, warranting further investigation into its diagnosis and treatment options.
VEXAS syndrome.
Int J Hematol
September 2025
Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fuku-Ura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
Article Synopsis
- VEXAS syndrome is a newly discovered autoinflammatory disease in adults caused by mutations in the UBA1 gene, leading to immune system activation and symptoms like fever and joint inflammation.
- The syndrome is associated with blood disorders and specific blood cell changes, which can serve as indicators for diagnosing UBA1 mutations in symptomatic patients.
- Treatment options are limited, but hematopoietic stem cell transplantation is the only potential cure, particularly for younger, healthier patients experiencing severe symptoms or complications.*